Icotinib is an orally active, first-generation EGFR TKI, one of the standard drugs for treating advanced NSCLC in China.[19] Our case showed that patient with EGFR G719A/L833V double mutation is more likely to benefit from icotinib treatment. This evidence concerns the gene EGFR and non-small cell lung carcinoma.